FARN Insider Trading

Insider Ownership Percentage: 39.29%
Insider Buying (Last 12 Months): GBX 0
Insider Selling (Last 12 Months): £37,750

Faron Pharmaceuticals Oy Insider Trading History Chart

This chart shows the insider buying and selling history at Faron Pharmaceuticals Oy by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Faron Pharmaceuticals Oy Share Price & Price History

Current Price: GBX 245
Price Change: Price Decrease of -20 (-7.55%)
As of 05/21/2024 03:35 PM ET

This chart shows the closing price history over time for FARN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Faron Pharmaceuticals Oy Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/12/2023John PoulosInsiderSell5,000GBX 383£19,150
10/3/2023John PoulosInsiderSell5,000GBX 372£18,600
See Full Table

SEC Filings (Institutional Ownership Changes) for Faron Pharmaceuticals Oy (LON:FARN)

12.73% of Faron Pharmaceuticals Oy stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Faron Pharmaceuticals Oy logo
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Read More on Faron Pharmaceuticals Oy

Today's Range

Now: GBX 245
Low: 236
High: 267.50

50 Day Range

MA: GBX 152.58
Low: 117.50
High: 261

52 Week Range

Now: GBX 245
Low: 113
High: 370


33,548 shs

Average Volume

26,142 shs

Market Capitalization

£176.42 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy's top insider investors include:
  1. John Poulos (Insider)
Learn More about top insider investors at Faron Pharmaceuticals Oy.